Specialty Pharmacy

Acceptance is based on CheckMate -816 trial results where the agency granted priority review status to the Bristol Myers Squibb drug and assigned a PDUFA goal date of July 13, 2022.

Upadacitinib (Rinvoq) is a Janus kinase (JAK) inhibitor being investigated to treat rheumatoid arthritis, Crohn disease, ulcerative colitis, atopic dermatitis, psoriatic arthritis, axial SpA giant cell arteritis, and Takayasu arteritis

Jakob Jensen, PhD, professor in the Department of Communication at the University of Utah and member of the Huntsman Cancer Institute, discusses how the beliefs and perceptions of cancer among adults living in rural areas compared to those of adults living in urban areas.

Filgrastim-ayow is indicated for the treatment of neutropenia, which is commonly experienced by patients receiving chemotherapy.

Thomasina Morris, RPh, MHA, BCOP, pharmacist at Moffitt Cancer Center, discusses how dosing for rucaparib treatment is assessed to treat patients with ovarian cancer.

The agency addresses the inclusion of older individuals in cancer-studies, the designing and conducting of multiple expansion cohorts, and the expedited development of biologics and drugs.

The median survival time for individuals with SCC and treated with Merck’s pembrolizumab was 13.9 months compared with 8.8 months in the control arm.

Jakob Jensen, PhD, professor in the Department of Communication at the University of Utah and member of the Huntsman Cancer Institute, discusses rural residents’ beliefs and perceptions of cancer-related information in comparison with those of urban residents.

Thomasina Morris, RPh, MHA, BCOP, pharmacist at Moffitt Cancer Center, discusses the efficacy of rucaparib for approved indications based on clinical trial results.

Pacritinib becomes the first treatment approved to specifically address the needs of patients with cytopenic myelofibrosis.

Majority of heavily pretreated patients with multiple myeloma administered ciltacabtagene autoleucel (cilta-cel; Carvykti) achieved deep responses after 18-months follow-up.

The study met its primary goal by demonstrating pharmacokinetic equivalence in patients who switched multiple times between treatment with the 2 medicines.

Pharmacists hold a vastly underrecognized role within the care team—a role that offers a unique approach toward the therapeutic management of rare diseases.

Thomasina Morris, RPh, MHA, BCOP, pharmacist at Moffitt Cancer Center, discusses how rucaparib is currently used when treating patients with ovarian cancer.

Thomasina Morris, RPh, MHA, BCOP, pharmacist at Moffitt Cancer Center, discusses the mechanism of action of rucaparib in recurrent and second line ovarian cancer, fallopian tube cancer, and peritoneal cancer.

Glecaprevir and pibrentasvir (Mavyret) is indicated for the treatment of chronic hepatitis C virus genotype 1-6 infections without cirrhosis or with compensated cirrhosis.

Combination netupitant and palonosetron capsules/fosnetupitant and palonosetron for injection (Akynzeo) is indicated to prevent acute and delayed nausea and vomiting associated with highly emetogenic chemotherapy.

Trastuzumab deruxtecan demonstrated clinically meaningful and statistically significant improvements in overall and progression-free survival, the company says.

The application is based on data showing that lisocabtagene provides clinically meaningful and statistically significant improvement for those with relapsed or refractory large B-cell lymphoma.

Data from the CALIBRATE and CAPELLA trials show high rates of virologic suppression with the capsid inhibitor.

The drug combination reduced the risk of disease progression by 34% versus the standard of care in first-line metastatic castration-resistant prostate cancer, clinical trial results show.

Cohort H of the phase 1b/2 EV-103 trial enrolled patients with MIBC who were eligible for surgical treatment but ineligible for cisplatin-based chemotherapy.

The investigators identified this in 9% of relapsed cases of pediatric acute myeloid leukemia, but it also was present in primary samples.

Dalpiciclib added to fulvestrant (Faslodex) was found to significantly prolong progression-free survival compared with fulvestrant monotherapy in patients with hormone receptor–positive, human epidermal growth factor receptor 2-negative advanced breast cancer.

Just 2 of 41 nutritionists interviewed reported using a validated screener, while 4 others said they use other tools, such as screening questions developed by other organizations, results show.

Ixekizumab (Taltz) is indicated for the treatment of conditions such as plaque psoriasis, psoriatic arthritis, active ankylosing spondylitis, and non-radiographic axial spondyloarthritis.

The continued upward trend in testing and vaccination demand, coupled with staffing shortages, technology gaps, and never-ending to-do lists, exacerbates spikes in patient volume and workload for pharmacy professionals.

FDA to evaluate adagrasib for the treatment of patients with non–small cell lung cancer with tumors that have a KRAS G12C mutation.

Results of CheckMate-9ER trial in first-line advanced renal cell carcinoma will be featured in 2 poster presentations at the American Society of Clinical Oncology 2022 Genitourinary Cancers Symposium.

The common-weight loss plan synergizes with chemotherapy to triple survival time compared with the treatment alone in rigorous mouse models of PDAC, the analysis shows.